Jose Daniel Subiela
Overview
Explore the profile of Jose Daniel Subiela including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scilipoti P, Longoni M, de Angelis M, Zaurito P, Slusarczyk A, Soria F, et al.
BJU Int
. 2025 Feb;
PMID: 39967051
Objective: To assess the oncological outcomes of patients with high-risk (HR) and very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC) treated with upfront radical cystectomy (RC) vs Bacillus Calmette-Guérin (BCG) instillations...
2.
Gallioli A, Uleri A, Verri P, Tedde A, Mertens L, Moschini M, et al.
Eur Urol Focus
. 2025 Feb;
PMID: 39894734
Background And Objective: Data about the mid- and long-term oncologic outcomes of endoscopic kidney-sparing surgery (eKSS) for upper tract urothelial carcinoma (UTUC) are scarce. Therefore, we aimed to summarize the...
3.
Tresh A, Del Giudice F, Li S, Basran S, De Berardinis E, Carino D, et al.
BJUI Compass
. 2025 Jan;
6(1):e481.
PMID: 39877570
Objectives: To assess the impact of a positive history of venous thromboembolism (VTE) on perioperative outcomes, including length of in-hospital stay, readmission rates, 90-day postoperative complications, and healthcare costs in...
4.
Scilipoti P, Longoni M, de Angelis M, Zaurito P, Massiet A, Dutto D, et al.
BJU Int
. 2025 Jan;
PMID: 39797535
Objective: To evaluate the oncological efficacy and safety of sequential intravesical gemcitabine/docetaxel (Gem/Doce) therapy in a European cohort of patients with high-risk and very-high-risk non-muscle-invasive bladder cancer (NMIBC) after previous...
5.
Yanagisawa T, Mori K, Matsukawa A, Kawada T, Katayama S, Laukhtina E, et al.
Target Oncol
. 2024 Nov;
20(1):57-69.
PMID: 39535690
Context: Adjuvant immune checkpoint inhibitors (ICIs) have recently emerged as guideline-recommended treatments of high-risk muscle-invasive urothelial carcinoma (MIUC). However, there is limited evidence regarding the optimal candidates and the differential...
6.
Laszkiewicz J, Krajewski W, Sojka A, Nowak L, Chorbinska J, Subiela J, et al.
Diagnostics (Basel)
. 2024 Sep;
14(17).
PMID: 39272712
Upper tract urothelial carcinoma (UTUC) is a rare but aggressive neoplasm. Currently, there are few reliable and widely used prognostic biomarkers of this disease. The purpose of this study was...
7.
Guerrero-Ramos F, Subiela J, Rodriguez-Faba O, Aumatell J, Manfredi C, Bozzini G, et al.
Bladder Cancer
. 2024 Jul;
8(4):339-357.
PMID: 38994181
Background: Several classifications have been reported to stratify non-muscle-invasive bladder cancer (NMIBC) in risk groups according to the probability of recurrence and progression. Objective: To systematically review the current evidence...
8.
Scilipoti P, Slusarczyk A, de Angelis M, Soria F, Pradere B, Krajewski W, et al.
Eur Urol Oncol
. 2024 Jun;
7(6):1293-1302.
PMID: 38902138
Background And Objective: Intravesical mitomycin C (MMC) instillations are recommended to prevent recurrence of intermediate-risk non-muscle-invasive bladder cancer (IR-NMIBC); however, the optimal regimen and dose are uncertain. Our aim was...
9.
Gonzalez-Padilla D, Subiela J, Villacampa-Auba F
Transl Androl Urol
. 2024 May;
13(4):639-642.
PMID: 38721284
No abstract available.
10.
Pichler R, Stablein J, Mari A, Afferi L, DAndrea D, Marcq G, et al.
J Clin Med
. 2024 Apr;
13(7).
PMID: 38610796
In non-muscle invasive bladder cancer, Bacillus Calmette-Guérin (BCG) responders benefit from strong Th1-type inflammatory and T cell responses mediating tumor rejection. However, the corresponding lack of anti-inflammatory Th2-type immunity impairs...